This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.93% per year. These returns cover a period from January 1, 1988 through October 6, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Stock Market News for October 19, 2016
by Zacks Equity Research
Upbeat earnings results led the benchmarks to close in the green on Tuesday
Market News Over Summer Vacation: PFE, AZN, TSLA, LZB
by Mark Vickery
You know you're in a slow news cycle when the market focus is on a Janet Yellen speech that doesn't happen until Friday, and no one expects any action to come of it anyway.
M&A Boosts Intersil, Syngenta and Medivation in Pre-Market
by Mark Vickery
We???re seeing big gains among smaller companies ready to be purchased by much bigger fish: PFE, MDVN, SYT, ISIL.
New Research Reports for Pfizer, Cisco & Visa
by Sheraz Mian
Today's must-read reports are for Pfizer (PFE), Cisco (CSCO) and Visa (V).
Q2 Earnings Reports Come in Mixed, Futures Down Slightly
by Mark Vickery
Q2 earnings season may have passed the midway point last week, but plenty of important companies are reporting earnings this morning: PFE, PG, MNT, CVS, SODA and RCL.
Don't Make It Complicated, Own Drug Stocks
by John Blank
The basic ingredients for rising drug demand -- the frailties that accompany aging -- are going to be there for the next 2 decades, in the USA and elsewhere.
Bull of the Day: Pfizer (PFE)
by Neena Mishra
Bet on this big pharma stock for growth, stability and income.
Bear of the Day: AbbVie (ABBV)
by Kevin Cook
Estimates were already sliding before the Feds took up the patent fight by "hopeful rival" Coherus
Stock Market News for May 04, 2016
by Zacks Equity Research
Stock Market News for April 07, 2016
by Zacks Equity Research
Benchmarks closed in the green on Wednesday following gains in biotech and energy stocks
Stock Market News for March 22, 2012
by Zacks Equity Research
Gains in healthcare and telecom stocks helped the benchmarks end marginally higher on Monday.
This Week's Top Value Stocks: (PFE) (MYL)
by Tracey Ryniec
Looking for the best value stocks? Tracey Ryniec, Stock Strategist at Zacks Investment Research, discusses two stocks that might be worth a closer look by value investors: Pfizer (PFE) and Mylan NV (MYL).
Pharma Industry Outlook: Pricing Pressure and M&As in Focus
by Arpita Dutt
According to a tracking poll, most Americans (72%) find drug costs unreasonable and 74% are of the view that drug companies put profits before people.
Pharma Industry Outlook: Pricing Pressure and M&As in Focus
by Arpita Dutt
According to a tracking poll, most Americans (72%) find drug costs unreasonable and 74% are of the view that drug companies put profits before people.
Q1 Earnings Scorecard - S&P 500 vs. Russell 2000
by Sheraz Mian
The picture emerging from the Q1 earning season is one of widespread weakness.